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“As a matter of fact,  
we know practically nothing of the causation of eclampsia.  
 
A theory has only to be set up by one investigator  
to be knocked down by another,  
and since there are a large number of theories advanced,  
we must give both sets of workers credit for the immense amount of labor and time 
consumed in building up these theories  
and in knocking them down.” 
 
Joseph Bolivar DeLee 
Read before the Chicago Gynecological Society, 
December 16, 1904 
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ABSTRACT 
 
Background and objectives 
	
Evidence supporting an association between HPV infection and pre-eclampsia has 
recently been published. Pre-eclampsia is a common, serious complication of 
pregnancy of complex aetiology that to date has not been fully described. Human 
papillomavirus (HPV) is a ubiquitous, DNA-virus with tropism for human mucosal 
commonly found in the female genital tract. Association between placental HPV 
infection and preterm labour and pregnancy loss has previously been described. This 
study tested the hypothesis that an association exists between HPV in the placenta 
or the cervix and clinical pre-eclampsia, or levels of its associated biomarkers, 
soluble fms-like tyrosine kinase (sFLT1) and placental growth factor (PlGF). 
Methods 
Women with pre-eclampsia were matched to healthy controls. All subjects were 
delivered by caesarean section, and cervical and placental samples were collected at 
the time of delivery. These samples were tested for HPV using a polymerase chain 
reaction (PCR) assay. Serum levels of soluble fms-like tyrosine kinase (sFLT1) and 
placental growth factor (PlGF) at the time of delivery were tested. Placental and 
cervical HPV was compared to the outcomes of clinical pre-eclampsia and serum 
sFLT1 and PlGF levels. 
Results and conclusion 
While clinically apparent disease was associated with increased levels of sFLT1 and 
decreased levels of PlGF, HPV was not detected in any of the placental specimens 
using the PCR assay. As a result, no association was found between placental HPV 
detection and clinically apparent pre-eclampsia or deranged serum levels of sFLT1 or 
PlGF. HPV was very common in cervical samples and showed a non-significant trend 
towards negative association with clinical pre-eclampsia and sFLT1, and a positive 
association with PlGF.  This may be an effect of cervical HPV infection on the 
vascular endothelial growth factor (VEGF) signalling system that may explain its 
association with miscarriage. 
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1. INTRODUCTION 
 
Pre-eclampsia is a serious complication of pregnancy of complex aetiology that to 
date is not completely understood. The search for factors that may play a role in the 
development of the disease is ongoing. An imbalance of pro- and anti-angiogenic 
factors of the vascular endothelial growth factor (VEGF) signalling protein family and 
their receptors are thought to play a central role in the disease process (1). Soluble 
fms-like tyrosine kinase-1 (sFLT1), a circulating splice variant of the VEGF-receptor-
1, and placental growth factor (PlGF), a member of the VEGF family largely derived 
from the placenta, are the most widely used biomarkers in clinical studies of pre-
eclampsia (2).  
 
Human papillomavirus (HPV) is a ubiquitous, small, double-stranded DNA-virus that 
displays tropism for human mucosal and cutaneous epithelial tissues. It causes 
verrucomatous lesions in the skin and condylomatous lesions of the mucosa. 
Infection may also be latent with no clinical manifestations visible. In infected cells it 
integrates into the host DNA and interferes with mechanisms that inhibit cell division. 
It is well-described as a carcinogenic factor in cervical and oropharyngeal mucosa 
(3,4). 
 
The common prevalence of HPV in the genital tract raises the possibility that it may 
have a role in adverse pregnancy outcomes. An association between detection of 
HPV in products of conception in preterm labour (5) and pregnancy loss (6) has been 
reported in observational studies.  Evidence for a role for cervical or placental HPV in 
pre-eclampsia is conflicting, but recent studies have reported an association between 
presumed cervical (7) as well as demonstrated placental HPV infection and pre-
eclampsia (8). 
 
This experimental research study tests the hypothesis that placental or cervical HPV 
is associated with clinical pre-eclampsia, or with changes in the serum levels of 
sFLT1 and PlGF. 
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2. LITERATURE REVIEW 
 
2.1 Pre-eclampsia 
 
2.1.1 Introduction 
 
Pre-eclampsia, the clinical syndrome of hypertension, proteinuria and organ system 
dysfunction is one of the biggest challenges of obstetric care. It remains one of the 
leading killers of mothers in both developed and developing countries, and causes 
severe morbidity (9).  The proven cure is delivery, but this often results in prematurity 
at birth, so that in its resolution pre-eclampsia causes neonatal morbidity. There are 
few other instances in obstetrics where the well-being of the mother and the fetus 
can be so diametrically opposed. 
 
Pre-eclampsia remains incompletely understood. It was first named “Krankheit der 
Theorien” or the “disease of theories” by the German obstetrician Paul Zweifel (1848-
1927) in his textbook Lehrbuch der Geburtshülfe (10). This description has been 
repeatedly re-examined by different writers (11–14) but remains apt. Despite intense 
scientific scrutiny, the pathophysiology of the disease defies easy description and 
definition. 
Much of the existing knowledge on pre-eclampsia is drawn from observational cohort 
studies. Many of the known risk factors for pre-eclampsia have been discovered in 
this way. For most of the risk factors so identified, odds ratios achieving statistical 
significance may be expressed. However, not all of them have clinical utility. Few 
screening risk factors have proven robust enough to form the basis for effective 
preventative treatment (15), and the search for effective screening tools continues. 
 
Pre-eclampsia may manifest with a variety of clinical presentations. This reflects the 
endothelial lesion that is the hallmark of the disease, and virtually any tissue, organ 
or system may be affected. The observation that the presence of placental tissue is 
the mandatory precondition for the development of pre-eclampsia implicates 
pathophysiology in the placenta as the source of the disease (16). 
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Many observations and theories of the nature of the placental pathology have been 
proposed, starting with the publication in 1958 of the observation that remodelling of 
the myometrial spiral arteries is incomplete by Dixon and Robertson working in 
Jamaica (17). However, this widely-described pathological finding in the placenta is 
not invariably present in pre-eclampsia, and the mechanism by which it may 
precipitate pre-eclampsia is likewise subject to much theorizing. Indeed, ultimately 
whether this finding is the cause or the consequence of the disease is not settled. 
 
In recent decades measurable serum biomarkers of pre-eclampsia have been 
identified. Prominent among these are anti-angiogenic factors (sFLT1) and soluble 
endoglin (sEng) (18). While these show promise in determining the prognosis of the 
disease (19) and may come to play a role in early screening, how, and indeed 
whether they are involved in the pathophysiology of the disease is still not completely 
understood. 
 
2.1.2 Historical aspects of pre-eclampsia 
 
Pre-eclampsia is defined by the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) as new-onset hypertension after 20 weeks’ gestation, with either 
proteinuria, or evidence of organ system dysfunction (20). There are several other 
internationally recognized sets of diagnostic criteria published by major professional 
bodies such as the American College of Obstetrics and Gynecology (ACOG) in the 
United States (21), the Society for Obstetric Medicine of Australia and New Zealand 
(SOMANZ) in Oceania (22) and the National Institute for Clinical Excellence and 
Health (NICE) in the United Kingdom (23).  
 
While there are differences in approach and diagnostic criteria, they all contain 
certain key diagnostic elements. These are hypertension with onset in the second 
half of pregnancy, accompanied by proteinuria or other organ system dysfunction 
(20–23). Each of these represents in its own way a major breakthrough in the study 
of pre-eclampsia. 
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At least some of the manifestations of pre-eclampsia as a disease of pregnancy had 
been observed for millennia. A serendipitous recognizable description of pre-
eclampsia as ‘drowsiness and headache accompanied by heaviness and 
convulsions’ already appears in the Prognosis, one of the ancient texts from the 
school of Cos, thought to predate Hippocrates (24). Some authors also claim that 
recognizable descriptions of eclampsia exist in ancient Chinese and Egyptian 
writings (25). 
 
During the middle ages in Europe, childbirth was the realm of lay midwives. Further 
record of eclampsia was only made after trained physicians became increasingly 
involved in labour and delivery in the seventeenth and eighteenth centuries, 
especially in France. Francois Mariceau (1637-1709) discussed convulsions in 
pregnancy and labour in his treatise Traité des maladies femmes grosses et 
accoucheés (1688), but did not distinguish eclamptic convulsions from epilepsy (26). 
 
Eclampsia was first formally distinguished from epilepsy by Francois Boissier de 
Sauvages (1706-1767). He proposed a classification system for convulsions, 
distinguishing chronic “epilepsy” from acute “eclampsia”, which included “eclampsia 
parturiemtum” as acute convulsions during labour (26). 
 
The description of the syndrome remained limited to the symptoms of headache, 
oedema and convulsions – essentially a description of eclampsia and its prodrome, 
until two key discoveries during the nineteenth century laid the foundation of the 
current definition of pre-eclampsia. These were the discovery of the association of 
proteinuria and hypertension with the classical symptoms of oedema, headache and 
convulsions. These two observations can be rapidly and cheaply made, and remain 
the cornerstone of pre-eclampsia screening in most of the world more than a century 
later. 
 
In France the pathologist François Rayer (1793-1867) found protein in the urine of 
three pregnant women with oedema in 1840. This was followed in November 1843 by 
the simultaneous publication by John Charles Lever (1811-1858) and James Young 
Simpson (1811-1870) of the observation of albumin in the urine of eclamptic patients 
(27).  
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The association of hypertension with proteinuria in pregnancy was first described by 
Charles Vinay (1845-1908) in 1894 in Paris. Henri Vaquez (1860-1936) and Pierre 
Nobécourt (1871-1943) first extended this association to eclampsia in a paper in 
1897 (26). Again it took time for hypertension and proteinuria in pregnancy to be 
distinguished from chronic renal disease with proteinuria, or Bright’s disease, as it 
was also known. Once established, blood pressure measurement subsequently 
became the screening observation of choice for predicting eclampsia. 
 
Once these diagnostic criteria of proteinuric hypertension in pregnancy were known, 
the study of pre-eclampsia proceeded on a firmer footing during the twentieth 
century, and large observational studies could be carried out to determine the 
epidemiology of what came to be termed pre-eclampsia (26).  
 
2.1.3 Epidemiology and demographic risk factors for pre-eclampsia 
 
The true incidence of pre-eclampsia in a population is seldom known. Incidence rates 
are often estimated from sometimes very biased samples. The incidence has been 
quoted as 3-5% (28). In addition, pre-eclampsia adds disproportionally to obstetric 
morbidity. Women with pre-eclampsia are significantly more likely to suffer severe 
outcomes, near-misses or death (9). Hypertension, including pre-eclampsia, was 
responsible for 640 maternal deaths (14.77% of the total) in South Africa for the 
2011-2013 triennium (29). 
 
Making comparisons between populations is problematic as the diagnostic criteria 
used may differ. The availability of screening and antenatal care between countries 
may also vary. There may also be selection bias present if the sample reported was 
drawn from women who delivered in hospital in countries with high rates of home 
birth or low rates of antenatal care access. With that in mind, while the reported 
incidence varies among populations, it does so within a range of 1.4 to 4.6 per cent 
with few outliers outside this range.  
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A large review of eight similar-sized population databases from New South Wales, 
Western Australia, Sweden, Norway, Scotland, Massachusetts, Denmark and Alberta 
found rates of pre-eclampsia that varied from 1.4% in Alberta to 4.0% in Norway (30). 
Secondary sources give some impression of a similar situation in developing 
countries. Secondary analysis of the World Health Organization Multi-country Survey 
on Maternal and Newborn Health showed reported incidence of pre-eclampsia in 27 
countries in Africa, South America and Asia. The incidence ranges from 0.46% in 
Niger to 4.6% in Brazil, with Mongolia (6.71%) and Nicaragua (7.67%) notable 
outliers (31). 
 
Prospective cohort studies, which should in theory provide the most accurate 
reflection of the incidence, are congruent with the above ranges. A prospective 
cohort study from Switzerland took a sample of 1300 women who presented for 
booking between 11-14 weeks and followed them for the duration of the pregnancy. 
The sample had an incidence of pre-eclampsia of 2.31% with a 95% confidence 
interval of 1.62-3.28% (32). 
 
In South Africa, studies examining possible risk factors for pre-eclampsia give an 
idea of the incidence of pre-eclampsia. Frank et al studied a random sample of 
pregnant women in Soweto for the effects of HIV (Human immunodeficiency virus) 
seroprevalence on the incidence of pre-eclampsia-eclampsia and found an overall 
incidence for hypertension of 17.3% and for pre-eclampsia of 5.7% (33). 
 
Pre-eclampsia is more common in older women. In studies that dichotomise age 
above and below 35 years, the association between higher age and pre-eclampsia is 
straightforward (34). Similarly, when women are sorted into age brackets of five 
years, there is a linear relationship between increasing age and pre-eclampsia 
incidence (35). 
 
Pre-eclampsia is more common in first pregnancy. This was first published by 
Francois Mariceau who observed that “primigravidas are at far greater risk of 
convulsions than multiparas.”(24) This medieval observation has stood the test of 
time. Observation from the Swedish Medical Birth Register over 19 years covering 
763 795 births found a 4.1% risk of pre-eclampsia in first pregnancies and a 1.7% 
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risk in higher-order pregnancies overall (36). The protective effect of previous 
pregnancy however is lost, and indeed reversed to statistically significant degree, if 
the outcome of the previous pregnancy was a preterm delivery or second trimester 
loss (37).  
 
One of the strongest risk factors for pre-eclampsia is a previous pregnancy 
complicated by pre-eclampsia. In the analysis of the Swedish Medical Birth Register 
the incidence for pre-eclampsia in subsequent pregnancies in women who previously 
had pre-eclampsia increased from an overall risk of 4.11% in first pregnancies to 
14.69% in subsequent pregnancies. This implies that an inherent susceptibility to the 
disease exists in some women. (35) 
 
The effects of change of partner on the risk of pre-eclampsia are controversial. 
Increased length of exposure to partner sperm appears to have a protective effect 
(38,39). In addition, pregnancies conceived using donor sperm (implying minimal or 
no pre-conception sperm exposure) have an increased risk of pre-eclampsia (40,41). 
On the other hand, large registry based studies showed that after statistical 
correction for inter-pregnancy interval, this effect disappears and even reverses (42). 
However, the validity of this statistical approach has also been questioned (43). 
 
The heritability of pre-eclampsia is complex and is likely to be multi-factorial. 
Although the reported numbers are small (two out of four), concordance for pre-
eclampsia in monozygotic twins have been reported (44). In addition, the presence of 
a second genome in the placenta makes the analysis of heritability factors in pre-
eclampsia even more complex (45).  
 
Pre-eclamptic women are more likely to have a sister with a history of pre-eclampsia 
(46). Similarly, they are more likely to be the daughters of women with pre-eclampsia. 
While this bears out some degree of heritability, the risk remains small, and 
inheritance remains far from predicting even a majority of pre-eclampsia (47).  
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2.1.4 Modifiable risk factors for pre-eclampsia 
 
In addition to the epidemiological features of affected women, there are some 
independent modifiable or variable risk and protective factors for pre-eclampsia. They 
can be roughly grouped for purposes of discussion. These groups are prior illness, 
diet, habits and environment and pregnancy-related factors. 
 
2.1.4.1 Prior illness 
 
The prior illnesses that bear increased risk for pre-eclampsia are a diverse group. 
These include diabetes mellitus, thrombophilia, auto-immune disorders, chronic 
hypertension and chronic renal disease (48). It is of note that they are all pro-
inflammatory diseases that carry increased risk for cardiovascular disease in general. 
 
Chronic hypertension and renal disease alone or in combination are associated with 
an increase in risk for pre-eclampsia (49). The difficulties in diagnosis that arises 
from the common diagnostic criteria has thus led to a separate group in the 
classification of hypertensive disorders of pregnancy: chronic hypertension with 
superimposed pre-eclampsia (20). Hopefully once reliable diagnostic biomarkers for 
pre-eclampsia are in wide use, this category may be done away with (2). Regardless 
of diagnostic difficulties, in the setting of hypertension existing prior to pregnancy, the 
risk of pre-eclampsia is increased (50).  
 
Pre-existing diabetes at the time of booking increases risk more than three-fold (51). 
The increase in risk is greater for type 1 than for type 2 diabetes (52). Gestational 
diabetes similarly holds increased risk (53). The risk is independent of body mass 
index (BMI) and an increase in BMI has an additive effect to the risk (52). In women 
with pre-gestational insulin-dependent diabetes mellitus, tighter control of 
hyperglycaemia as reflected by HBA1c level is associated with smaller increase in 
risk (54). 
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Inherited thrombophilia shows a weak association with risk for pre-eclampsia (55). A 
much larger risk is present with anti-phospholipid syndrome, the most important 
acquired thrombophilia in pregnancy (56). Similarly auto-immune disease, primarily 
systemic lupus erythematosus, is associated with increased risk (57). 
 
2.1.4.2 Diet, habits and environment 
 
A number of maternal environmental factors modify risk of developing pre-eclampsia. 
An increase in BMI has a linear relationship with risk for pre-eclampsia (52). Dietary 
deficiency of calcium and residence at altitude are associated with increased risk 
(58). Tobacco smoking during the third trimester is associated with a decreased risk 
(59). 
 
Increased BMI has a linear relationship with pre-eclampsia risk. This relationship 
holds true in multiple large reported series (51,53,60). This linear relationship has 
been shown independent of other disease associated with obesity such as diabetes 
and hypertension (52). 
 
Women living at altitudes higher than 3000m have an increased risk of pre-eclampsia 
compared to women living at lower altitudes (61). The evidence for this comes from 
studies in Latin America, where women living at high altitudes in the Andes were 
compared to women near sea-level. Whether a linear relationship between altitude or 
partial pressure of oxygen and the incidence of pre-eclampsia exists, remains to be 
determined. 
 
The observation that a deficiency of dietary calcium is associated with pre-eclampsia 
was first made in the 1980s (62) and has been the subject of intense investigation. 
For women with a deficiency, calcium supplementation can indeed decrease the 
incidence (58). Whether this is due to its effects on blood pressure in later pregnancy 
or whether it has an intrinsic role in the prevention of the initiation of the disease 
process has not been determined and is the subject of a large ongoing randomized 
controlled trial (63). 
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The smoking of tobacco products during the third trimester of pregnancy has a 
protective effect against pre-eclampsia (59). The effect is not seen for women who 
smoke in earlier pregnancy, and holds true for those who start smoking in the third 
trimester. Non-combustion use of tobacco products do not show the same effects 
(59). 
 
2.1.4.3 Pregnancy-related factors 
 
The nature of the conceptus affects the risk of pre-eclampsia. Multiple gestation (64) 
and molar pregnancy (16) are associated with increased risk. Pregnancies conceived 
by artificial reproductive techniques have varying increases in risk (65).       
 
Women with twin gestation have a more than two-fold increase in risk for pre-
eclampsia (66). The increased risk is common to both the early severe and later-
onset pre-eclampsia (64). The zygosity of the twins in some studies do not have an 
effect on the rates of pre-eclampsia (67). Other investigators however found 
differences when stratifying by severity of disease, but again overall no significant 
difference in rates (68).  
 
Current diagnosis and management of molar pregnancy means that most molar 
pregnancies are terminated during the first trimester. However, in historical reports, 
molar pregnancies were associated with a significant increase in risk of pre-
eclampsia (16). This observation is responsible for the insight that trophoblastic 
tissue, and not a fetus, is the prerequisite for the development of pre-eclampsia.  
 
Pregnancies arising from assisted reproductive techniques show increased risk of 
hypertensive disorders (69). This effect is seen in both singleton and twin gestations. 
The risk is greater for frozen-thawed cycles than for fresh cycles (65). In addition, as 
noted above, risk is increased when donor sperm is used, and decreases with the 
number of cycles of intra-uterine insemination with donor cycles (40). There is no 
difference in risk between in vitro fertilization and intra-cytoplasmic sperm injection 
(65). 
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The effect of HIV infection on risk has received a deal of attention with some authors 
suggesting a decrease in risk in women with HIV infection (70). This has been 
postulated to be as result of the immune-modulating effects of HIV infection. This 
finding has not been borne out by all investigations (33). In addition, the provision of 
anti-retroviral drugs to women with HIV, and the possible confounding effects is now 
impossible to separate from the effects of HIV. A large meta-analysis concluded that 
there is currently no evidence of HIV changing the risk for pre-eclampsia (71).  
 
Many other factors have been investigated for a role in the development of pre-
eclampsia. In some series, previous caesarean section (72), national economic 
disasters (73), obstetric cholestasis (74) and even ambient temperature around the 
time of conception (75) were found to have some weak association with pre-
eclampsia. Although interesting in passing, these findings are unlikely to be helpful in 
either elucidating the pathogenesis or in predicting incidence of the disease. 
 
2.1.5 Screening for pre-eclampsia 
 
Given the many known risk factors for pre-eclampsia, the logical continuation would 
be to construct screening models for pre-eclampsia. Simple models based on history 
and identified risk factors are in use in the UK (23), and more complex models that 
include the use of biomarkers and ultrasound investigations have also been 
proposed and trialled (76). 
 
The primary criticism against any attempt at screening is the observation that pre-
eclampsia fails to meet several of Wilson and Jungner’s criteria for screening (77). 
Specifically, the requirements for a recognisable latent period and understanding of 
the natural course of the disease are not definitively met. 
 
In favour of screening is the existence of two well-studied preventive interventions for 
pre-eclampsia. The first of these is the use of low-dose aspirin. This has been shown 
to be of benefit in decreasing the risk for pre-eclampsia in women at high risk of pre-
eclampsia based on clinical risk factors (78). The second is the use of supplementary 
calcium in women with low dietary calcium intake, or in women at high risk of 
developing pre-eclampsia (58). 
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The use of low-dose aspirin is more effective if initiated before 16 weeks’ gestation. 
The odds ratio for developing pre-eclampsia and severe pre-eclampsia was 0.3 and 
0.6 in one meta-analysis; this translated to a number needed to treat of 19 at-risk 
women to prevent one case of pre-eclampsia (79).  
 
The Cochrane Library meta-analysis showed a relative risk reduction of 17% (78). 
The performance of using only maternal characteristics as a screening tool to 
determine risk has been quoted as including only 36% of women at risk of developing 
early pre-eclampsia with a false positive rate of 5% (80). Assuming a baseline rate of 
pre-eclampsia of 3%, this will translate to a number needed to treat of 29. 
 
The difficulty in making recommendations based on the evidence can be illustrated 
by the recommendations for considering women to be at high risk for developing pre-
eclampsia from two geographically neighbouring societies. The Society of 
Obstetricians and Gynaecologists of Canada name no less than 10 high and 13 
moderate risk factors for developing pre-eclampsia (81). In contrast, the American 
Congress of Obstetricians and Gynecologists Task Force identifies only two risk 
factors that indicate the initiation of prophylactic aspirin (21). 
 
The situation regarding the use of calcium is also not straightforward. There is a 
benefit in women with a low dietary calcium intake of less than 600mg/day(58), and 
supplementation is recommended by the World Health Organisation (82). The 
evidence for women with normal dietary calcium intake at high risk for pre-eclampsia 
is less convincing, and currently the use of calcium as a preventive agent for women 
with normal dietary intake of calcium is not recommended by any of the major 
societies. 
 
A novel statistical method has been proposed to develop a competing-risks model for 
the prediction of pre-eclampsia (76). The calculation of risk is based on the 
assessment of first trimester uterine artery Doppler studies as well as measurement 
of mean arterial pressure, PlGF and pregnancy-associated plasma protein-A (PAPP-
A). The performance of this combination of measurements in the competing-risks 
calculation model has been reported as a sensitivity of 93% for the development of 
pre-eclampsia before 34 weeks at a false-positive rate of 5% (76). 
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While this proposed model appears to have significant benefits over traditional 
methods of risk assessments, its cost-effectiveness and ultimate effect on pregnancy 
outcome is still to be determined and its routine use is not recommended by the 
American College of Obstetricians and Gynecologists in a committee opinion (83). 
	
2.1.6 Aetiology of pre-eclampsia 
 
Synthesizing the many identified risk factors into a coherent theory on the aetiology 
of pre-eclampsia remains a daunting prospect. There are however a few central 
observations that are incorporated into current understanding of the aetiology of the 
disease.  
 
First of these is that the presence of a placenta is the pre-condition for the disease. 
Secondly, there is a strong association of failure of trophoblastic invasion and 
remodelling of the maternal myometrial spiral arteries in early pregnancy with the 
development of pre-eclampsia. Thirdly, the manifestations of the disease are the 
result of systemic endothelial dysfunction. 
 
These observations form the basis of a two-stage model of development of pre-
eclampsia (84). The first stage is characterised by abnormality of the transformation 
of the maternal spiral myometrial arteries by invading cytotrophoblasts. The second 
stage is characterised by systemic maternal vascular inflammation and endothelial 
dysfunction. This dysfunction of the maternal vascular bed results in the clinical 
features of organ system dysfunction (85). 
 
The association of abnormality of maternal spiral artery invasion and remodelling was 
first published more than half a century ago (17). In normal human pregnancy, extra-
placental cytotrophoblasts invade the decidua and myometrium and migrate into the 
vessel walls of the spiral arteries of the uterine placental bed. The muscular wall of 
these arteries are then degraded and the vessels are transformed into dilated, low-
resistance flaccid vessels (86).  
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In some pre-eclamptic women, this process is incomplete, and the spiral artery walls 
remain muscular, so that the vessel lumen diameter remains the same (87). While 
the association of this incomplete remodelling with pre-eclampsia is well-described, 
its study is hampered by the difficulty of obtaining specimens for study, the tissues of 
the pregnant uterus not being safely available for biopsy. Animal models are not 
transferable to humans, as not all species display invasion and remodelling of the 
uterine spiral arteries (87). 
 
The mechanism, by which abnormal invasion leads to the systemic effects of pre-
eclampsia, is still not fully understood. Infarction is common in the placentae of pre-
eclamptic women, and the placental production of several anti- and pro-angiogenic 
proteins are altered (88). The stimulus for these changes have been proposed to be 
variously due to placental hypoxia (89), placental hypoperfusion and reperfusion with 
resultant oxidative stress (85) or mechanical shear stress due to the increased 
velocity of blood flow through the narrow vessels (90). 
 
2.1.7 Vascular endothelial growth factor family biomarkers and pre-eclampsia 
 
A bewildering array of possible biomarkers for pre-eclampsia has been described, 
with more than 15 biomarkers proposed for screening and diagnostic use (91). The 
group of biomarkers currently most examined are related to the VEGF signalling 
protein family and their receptors. The possible causative role of these ligands and 
their proteins was first raised in 2003 based on work in animal models (92). 
 
The VEGF system constitutes a family of signalling proteins. There are five variants 
of VEGF in humans, VEGF-A, -B, -C, -D, and PlGF. VEGF-A was the first described 
member, and stimulates angiogenesis. VEGF-B regulates embryonic angiogenesis, 
and VEGF-C and –D play a role in the regulation of lymphangiogenesis. There is no 
evidence of a role for VEGF-B, -C and –D in the development of pre-eclampsia (93). 
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There are three described receptors for VEGF. The first is VEGF-receptor-1, also 
known as fms-like tyrosine kinase-1 (FLT1). Fms-like tyrosine kinase is named for its 
similarity to the product of the fms gene, a membrane-bound colony stimulating 
factor-1 (CSF-1) receptor. The fms gene was first designated in 1982 (94) as a result 
of work in felines, describing the development of feline sarcoma as a result of 
infection with feline McDonough strain sarcoma virus, which carries genes for a 
variant of the fms gene (95).  
 
VEGF-receptor-2 is also known as kinase domain region (KDR). VEGF-receptor-3 is 
also known as fms-like tyrosine kinase-4 (FLT4), and acts as a receptor for VEGF-C 
and -D. sFLT1 is a splice variant of VEGFR-1 without the membrane-bound portion 
of the receptor that thus functions as a circulating decoy receptor. 
 
VEGF-A binds to both FLT1 and KDR, and causes increased vasodilation via 
prostacyclin and nitrous oxide production, angiogenesis and increased vascular 
permeability. Most of the cellular responses are elicited by binding KDR, with FLT1 
thought to act mostly as a modulating receptor (96).  
 
Soluble fms-like tyrosine kinase 1  is expressed in the placenta, and has been shown 
to be upregulated in vitro in a relative hypoxic environment (89). It has also been 
shown that early pregnancies that are destined for pregnancy loss have decreased 
serum levels of sFLT1 compared to pregnancies that progress (97). 
 
The initial work describing a possible role for sFLT1 in the development of pre-
eclampsia was done in a rat model. It was shown in vitro to cause endothelial 
dysfunction with vasospasm and increased vascular permeability. In pregnant rats 
increasing sFLT1 led to hypertension, proteinuria and glomerular endotheliosis that 
was rescued by the administration of exogenous VEGF (92). 
 
Despite the promise of these biomarkers, there are still many questions unanswered. 
An argument has been made that sFLT1 meets the Bradford Hill criteria for causation 
(98). However, although the differences in the means between pre-eclamptic women 
and healthy controls meet a high level of statistical significance, there is significant 
overlap of the levels between healthy and pre-eclamptic women. Indeed, the only 
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validated clinical use of sFLT1 to date is in combination with PlGF levels, as a rule-in 
prognostic test (19). Its use has been mooted to distinguish other causes of 
hypertension, proteinuria and thrombocytopaenia from pre-eclampsia in pregnant 
women, but widespread clinical use is still elusive. 
 
Many questions remain about the role of sFLT1 and sEng in pre-eclampsia. It has 
been shown that VEGF acts as a chemo-attractant for cytotrophoblast (99). Changes 
in the levels of sFLT1 appear to have an effect on the outcome of pregnancy long 
before invasion of the myometrial arteries take place (97). It may therefore be asked 
whether changes in the homeostasis system of the VEGF angiogenesis system is the 
cause, rather than the consequence of abnormal placentation. 
 
Also, the translation of results of animal models to humans is not straightforward. 
There are physical differences in the expressed VEGF in rats and humans. In 
addition, the circulating concentrations of VEGF and sFLT1 between humans and 
rats are different by some orders of magnitude. When taking into account the 
equimolar binding of sFLT1 and VEGF or PlGF, sFLT1 is not in high enough 
concentrations to make a large difference to the free circulating levels of VEGF (93). 
 
Finally, the sheer complexity of the VEGF system means that conclusions are not 
easy to draw. VEGF-A alone can be expressed as one of 7 isoforms of different 
molecular weights, and different affinities. In addition, depending on the splicing, 
isoforms may act as inhibitors rather than as agonists. Several other moieties also 
act as modulators of VEGF effects (93). 
 
Despite the many unanswered questions, the central place of the VEGF signalling 
system in the development of pre-eclampsia is widely accepted, and sFLT1 and 
PlGF levels should be considered as additional outcome measures in studies of 
clinical pre-eclampsia. 
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2.2 Human papillomavirus 
 
2.2.1 Biology of HPV 
 
Papillomaviruses are non-enveloped double-stranded DNA-viruses. They comprise 
the family Papillomaviridae, and are further sub-classified into genus, species, type 
and subtype. Papillomaviruses that have humans as host are termed human 
papillomaviruses (HPV) (4).  
 
HPV may infect cutaneous or mucosal squamous epithelium, although there is some 
overlap between types. Mucosal HPV types belong predominantly to the alpha-
papillomavirus genus, and may be further classified as high or low risk, according to 
its ability to immortalise keratinocytes. Thirteen types of HPV are associated with 
carcinoma of the cervix, and are consequently termed high risk HPV (hrHPV) (3). 
 
The HPV genome is a circular plasmid and comprises 10 genes, and expresses 8 
major proteins. E1, E2, E4, E5, E6 and E7 are termed early proteins and are involved 
in modifying the cell cycle and replication of the host cell. L1 and L2 are late proteins 
and make up the viral capsid necessary for extracellular survival and transmission. 
(100). E1 and E2 regulate viral replication, while E4 plays a role in disrupting the host 
cell defences to enhance infectivity.  
 
The early proteins E5, E6 and E7 interfere with the host cellular mechanisms, in 
particular those involved with regulation of cell replication and the cell cycle, which 
forms the basis of the carcinogenic potential of HPV. E5 is a small, pluri-potential 
protein that has been shown to interfere with many intracellular processes, including 
signalling growth factors (101).  
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E5 however is not necessary for oncogenesis, as this follows after viral DNA 
integration in the host cell DNA, where the E5 gene is often lost (102). E6 inhibits 
p53, a tumour suppressor gene that arrests the cell in G1 phase for DNA repair, and 
induces apoptosis if DNA repair does not take place (103). E7 binds to and 
inactivates Rb1, the product of the retinoblastoma gene-1. Rb1 is a tumour 
suppressor protein that arrests the cell cycle in G1, and deletion or inactivation of 
Rb1 is associated with retinoblastoma and other tumours (104). 
 
2.2.2 Epidemiology of HPV 
 
Given the importance of HPV to the development of cervical cancer, most studies of 
the prevalence have focussed on the prevalence of cervical HPV, in particular 
hrHPV. There is considerable variation of prevalence of HPV infection between 
geographical regions and age groups. It has been estimated that almost all sexually 
active women will be infected with at least one strain of HPV during her lifetime (105). 
 
In South African populations, two recent studies tested the prevalence of cervical 
HPV in large samples from Cape Town and Pretoria, and compared it to both HIV 
infection and cervical cytology abnormalities. In the Cape Town study, an overall 
HPV prevalence of 25.4% was found among 9421 women (106). In Pretoria, an 
overall prevalence of 74.6% and an hrHPV prevalence of 54.3% was found among 
1445 women (105). 
 
The prevalence of HPV infection in pregnancy has not been determined in South 
African populations before. In the United States, an overall prevalence of HPV of 
42% in pregnant women was found in one study, compared to 41% in non-pregnant 
controls (107).	
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2.2.3 Methods of testing for HPV 
 
Multiple methods exist for the detection of HPV. A complicating factor in comparing 
research done on HPV is the variation in methods of testing. Different testing 
modalities may also differ in the range of subtypes that they can detect (108). The 
comparative performance of different testing modalities is not always known. 
 
In general, formalin fixed, paraffin embedded tissue specimens can be tested using 
immunohistochemistry or in-situ hybridisation. Fresh specimens may be analysed 
using polymerase chain reaction (PCR) DNA amplification followed by hybridisation 
to detect different subtypes. Commercial assays assays differ in their sensitivity and 
in the range of HPV subtypes that they detect. Care must be taken in the collection 
and storage of specimens to avoid contamination and degradation of viral DNA 
leading to false positive and false negative results respectively (109). 
 
In a small study, the performance of L1 antibody immunohistochemistry was 
compared to PCR testing. Immunohistochemistry detected HPV in 78.9% of the 
specimens that tested positive by PCR (110) 
 
2.2.4 HPV and the placenta 
 
In the light of the widespread prevalence of HPV in the female genital tract, the 
association of HPV with pregnancy has been scrutinised. There is evidence for an 
association for HPV in early pregnancy loss (6), premature rupture of the membranes 
(111) and premature labour (5). 
 
HPV has also been shown to infect trophoblasts in vitro (5), and has been 
demonstrated in trophoblasts in spontaneously aborted products of conception (112). 
The observation that some infants have congenital HPV infection despite being 
delivered by Caesarean section (113) has led to attempts to detect HPV in the 
placenta and cord blood (114,115). Although demonstrated, it is rare. In one study 
from Belgium, chorionic villus sampling specimens were analysed for HPV using 
PCR, and yielded 2 positive out of 35 (115).  
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Another study from Finland of placentae delivered at term found 4.2% of 306 positive 
for HPV using nested PCR (114). A third study from Austria found 5.2% of 153 
placentae positive for HPV using the Hybrid Capture II test (116). 
	
2.3 HPV and pre-eclampsia 
 
McDonnold et al in Texas found that cervical HPV infection at the time of entry into 
antenatal care is associated with a roughly doubled risk of developing pre-eclampsia 
(7). This intriguing finding, although proving association and not causation, raises the 
exciting possibility of a novel, preventable mechanism in the development of pre-
eclampsia.  
 
In a second study, Hung et al in Otago studied a large series of placentae from 
women with preterm labour, pre-eclampsia, gestational diabetes and healthy 
controls. They found a high prevalence of HPV in the placentae studied, as well as a 
strong association between placental HPV and pre-eclampsia, with all the placentae 
from pre-eclamptic women showing HPV (8). 
 
The evidence however is conflicting, with previous studies finding no such 
association when testing mature placentae for HPV (5), or very little HPV in 
specimens collected from first trimester chorionic villus sampling (115). 
 
The theoretical underpinning for an association between HPV and pre-eclampsia is 
the ability of HPV infection to influence VEGF expression. It has been noted that HPV 
can in vitro induce VEGF production in infected tissues (117). Other researchers 
have found that increased endometrial VEGF levels led to upregulation of s-FLT 
expression in the placenta in a murine model (118). Thus decidual HPV may lead to 
increased VEGF and in turn upregulation of placental s-FLT, causing the systemic 
maternal complications of pre-eclampsia. 
 
Two separate circumstantial associations exist that provide further ground to suspect 
an association. The first observation is that usage of intra-uterine contraceptive 
devices are protective against cervical HPV infection and premalignant cervical 
lesions (119), and also against pre-eclampsia (120). 
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The second, perhaps more fanciful connection is between falling reported rates of 
pre-eclampsia in Australian populations (121), and the use of HPV vaccination in that 
country. Australia was the first large country to start the use of HPV vaccination in 
2007 (122), and was also the first to introduce a national vaccination programme. It 
would appear that the falling trend in pre-eclampsia incidence predates the 
introduction of the vaccine, but the fall in incidence has been sustained subsequent 
to the start of vaccination programmes. However, with its good record-keeping and 
close surveillance of HPV, Australia may in future provide stronger evidence of 
correlation. 
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3. MATERIALS AND METHODS 
 
3.1 Objectives 
 
3.1.1 Primary objective 
 
3.1.1.1 To determine if there is an association between the presence of HPV in the 
placenta at the time of delivery and clinically diagnosed pre-eclampsia. 
 
3.1.2 Secondary objectives 
 
3.1.2.1 To determine if there is an association between HPV infection in the cervix 
and clinically diagnosed pre-eclampsia. 
 
3.1.2.2 To determine if an association exists between the presence of HPV in the 
placenta and serum sFLT1 and PlGF levels at delivery in all subjects.  
 
3.1.2.3 To determine if an association exists between cervical HPV infection and 
increased serum sFLT1 and placental growth factor levels in all subjects. 
 
3.1.2.4 To determine if a correlation exists in the presence of HPV, and subtype 
distribution, between cervical specimens taken prior to caesarean section and 
placental specimens in all subjects. 
 
3.1.2.5 To determine if a correlation exists between HPV subtype distribution in 
cervical and placental specimens in all subjects. 
 
3.1.2.6 To determine if brush cytology specimens of the decidual surface of the 
placenta and chorionic membrane have a diagnostic yield comparable to tissue 
sample obtained from a flash-frozen placental specimen in all subjects. 
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3.2 Methods 
 
3.2.1 Definitions 
 
3.2.1.1 Hypertension is defined as systolic blood pressure of more than 140mmHg or 
diastolic blood pressure more than 90mmHg on two occasions, six hours or more 
apart, or a single reading with systolic blood pressure more than 160mmHg or 
diastolic blood pressure more than 110mmHg. 
 
3.2.1.2 Pre-eclampsia 
 
Pre-eclampsia is defined as hypertension arising for the first time after 20 completed 
weeks of gestation, with the presence of 1+ or more protein on protein dipsticks on 
two separate samples at least six hours apart, or a urine protein:creatinine ratio > 
30mg/mmol, or urinary protein excretion of more than 300mg over 24 hours. 
 
3.2.2 Study design 
 
The study was designed as a cross-sectional observational analytical case-control 
study to achieve objectives 3.1.1 (to determine if there is an association between the 
presence of HPV in the placenta at the time of delivery and clinically diagnosed pre-
eclampsia) and 3.1.2.1 (to determine if there is an association between HPV infection 
in the cervix and clinically diagnosed pre-eclampsia). The outcome in question is pre-
eclampsia, and the studied exposure is the overall, high- or low-risk subtype-specific 
presence of HPV in the placenta in objective 3.1.1 (to determine if there is an 
association between the presence of  HPV in the placenta at the time of delivery 
delivery and clinically diagnosed pre-eclampsia) and cervix in objective 3.1.2.1 (to 
determine if there is an association between HPV infection in the cervix and clinically 
diagnosed pre-eclampsia) at the time of delivery.  
 
In addition, for secondary objectives the data will be analysed as for a cross-sectional 
observational study to achieve objectives 3.1.2.2 (to determine if an association 
exists between the presence of HPV in the placenta and serum sFLT1 and PlGF 
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levels at delivery in all subjects) and 3.1.2.3 (to determine if an association exists 
between cervical HPV infection and increased serum s-Flt and placental growth 
factor levels in all subjects). The outcome here is serum levels of sFLT1, PlGF, and 
their ratio at delivery, compared to the exposures of placental (in objective 3.1.2.2) 
and cervical (in objective 3.1.2.3) HPV. 
 
In a similar fashion the study was considered as a cross-sectional observational 
study to achieve objectives 3.1.2.4 (to determine if a correlation exists in the 
presence of HPV, and subtype distribution, between cervical specimens taken prior 
to caesarean section and placental specimens in all subjects) and 3.1.2.5 (to 
determine if a correlation exists between HPV subtype distribution in cervical and 
placental specimens in all subjects).  
 
3.2.3 Sample size 
 
The study was planned as a pilot study with a limited number of participants. With a 
sample size of 40 and a case to control ratio of 1:1, with significance at 0.05 and 
power at 0.8, probability of exposure amongst controls of 0.4, this sample was 
powered to detect an odds ratio of 8.0 or greater. 
 
3.2.4 Study setting 
 
The study is set in two academic hospitals associated with the University of the 
Witwatersrand Department of Obstetrics and Gynaecology, Chris Hani Baragwanath 
Academic Hospital and Charlotte Maxeke Johannesburg Academic Hospital. These 
two hospitals cater to the urban population of Soweto and Johannesburg, and act as 
tertiary referral centres for other hospitals in the region.  
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3.2.5 Study population 
 
3.2.5.1 Case population 
 
The case population consists of women diagnosed with pre-eclampsia meeting the 
defined diagnostic criteria, delivering singleton pregnancies by caesarean section 
with intact fetal membranes, in the study hospitals. 
 
3.2.5.2 Control population 
 
The control population consists of women with no other systemic morbidities 
delivering singleton pregnancies by caesarean section with intact fetal membranes. 
	
3.2.5.3 Exclusion criteria  
 
Exclusion criteria were known modifiable risk factors for pre-eclampsia, hypertension 
with proteinuria present before 20 weeks’ gestation and women under the age of 18. 
Pre-existing diabetes mellitus, pre-existing hypertension, known anti-phospholipid 
syndrome, thrombophilia, renal and auto-immune disease and a family history of pre-
eclampsia were considered as modifiable risk factors for pre-eclampsia. In addition, 
women who have received a vaccination to HPV, and women who conceived by 
artificial reproductive techniques were excluded from the study. 
 
3.2.5.4 Participant recruitment 
 
Women meeting inclusion criteria were identified from the theatre booking lists at 
CHBAH and CMJAH daily during the data collection period. The identified women 
were approached and counselled on the study, and offered the opportunity to 
participate. 
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3.2.6 Data collection 
 
The data collection period ran from 1 December 2015 to 30 April 2016. Study data 
was collected and managed using the REDCap (Research Electronic Data Capture) 
electronic data capture tool hosted at the University of the Witwatersrand. REDCap is 
a secure, web-based application designed to support data capture for research 
studies. The data is encrypted and stored in an access-controlled environment in the 
Wits Data Center. After collection, identifying information will be removed from 
participant data. Each participant’s data was assigned a unique study number. A 
record matching unique study numbers with identifying data is kept securely by the 
investigator. 
	
3.2.7 Sample collection and storage 
 
Informed consent was obtained from women meeting the inclusion criteria using the 
informed consent form (Appendix D) prior to caesarean section by the principal 
investigator. The data sheet (Appendix E) was captured manually and entered 
electronically using REDCap to record diagnostic and demographic data and 
exposure to other risk factors for pre-eclampsia.  
 
Prior to caesarean section a cervical brush cytology specimen was obtained from 
participants using the standard method for collecting cervical smears, using a 
Cytobrush (NMS supplies, Johannesburg, South Africa). The specimens were stored 
in PreservCyt preservation solution (ThinPrep solution, Hologic, Marlborough, 
Massachussetts) and stored at between 2 and 8 degrees Celsius until testing at the 
testing laboratory according to the manufacturer’s guidelines. 
 
After delivery the placentae were collected and specimens prepared. Smear 
specimens were prepared by rinsing blood from the decidual surface of the placenta 
using tap water. The specimen was obtained using the Cytobrush. The decidual 
surface of the placenta was brushed from the centre of the placenta onto the edge of 
the decidual surface of the membranes, while rotating the brush so that the surface 
of the brush in contact with the placental surface was brushed in the direction of the 
placental edge. 
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After collection of the smear specimen, a full-thickness transmural placental 
specimen was collected. The specimens were flash-frozen and stored at -80 degrees 
Celsius until transfer to the testing laboratory (South African National Institute for 
Communicable Diseases STI and HIV section), where it was processed to obtain a 
300mg protein sample. 
 
In addition, prior to caesarean section, a blood sample was collected for the maternal 
serum s-Flt and Placental Growth Factor levels in a serum separator tube mark II 
(SST-II), centrifuged and frozen at -80 degrees Celsius until testing	
3.2.8 Laboratory analysis 
 
DNA was extracted from 120 specimens (40 cervical, 40 placental smear and 40 
flash-frozen placental samples) using the AmpliLute Liquid Media Extraction Kit 
(Roche Molecular Systems, USA) according to the manufacturer’s instructions.  HPV 
genotyping was be performed on extracted DNA using the Linear Array HPV 
Genotyping Test (Roche Molecular Systems, USA).   
 
This assay is a qualitative in vitro test that uses HPV DNA amplification by 
polymerase chain reaction (PCR) and nucleic acid hybridization for the detection of 
13 high-risk (HR) HPV genotypes (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
and 68) and 24 low-risk (LR) HPV genotypes (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 
64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and CP6108).  The probe for HPV 
type 52 is a mixed probe that cross-reacts with HPV-33, HPV-35 and HPV-58, 
therefore the presence of HPV-52 is only reported in the absence of the latter three 
types.  The assay contains an additional primer pair that targets the human ß-globin 
gene (internal control) to provide a control for cell adequacy, extraction and 
amplification. The manufacturer’s instructions are included as appendix F. 
 
Maternal serum was tested for s-Flt and PIGF using the Roche Elecsys Pre-
eclampsia Assay according to the manufacturer’s guidelines (Appendix G). 
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3.2.9 Data analysis 
 
3.2.9.1 Descriptive statistics 
 
The incidence of placental and cervical HPV in case and control group was 
expressed as proportions and standard error (SE) calculated. All other binary 
variables (parity, previous pregnancy loss and HIV status) were expressed as 
proportions and standard errors calculated. HPV subtypes were grouped as binary 
variables, for any types, high-risk and low-risk types only. In addition, HPV status 
was sorted into a categorical variable of no infection, single subtype infection and 
multiple subtype infection. 
 
Means and standard errors of continuous variables (age, gestation, birth weight, 
sFLT1 and PlGF levels) were calculated. Continuous variables were assessed for 
normality of distribution using histograms or skewness and kurtosis testing. 
 
3.2.9.2 Inferential statistics 
 
Binary variables were compared using Pearson’s Chi squared test. Binary and 
continuous variables were tested for association using unpaired Student’s t-test. 
Continuous variables were tested for association using Pearson’s correlation. A two-
sided p-value of 0.05 was used to determine significance. 
 
The potentially confounding variables of age, HIV status, BMI, parity and previous 
pregnancy loss were assessed for association with the outcomes of clinical pre-
eclampsia, sFLT1 and PlGF levels and corrected for by multiple regression. 
 
3.2.9.3 Data tools 
 
Data were analysed using Stata software (StataCorp. 2015. Stata Statistical 
Software: Release 14. College Station, TX: StataCorp LP).  
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3.3 Ethical considerations 
 
Ethics review approval was obtained from the University of the Witwatersrand Human 
Research Ethics Committee (Medical). A copy of the approval certificate is attached 
as appendix A. 
 
Because the presence of hrHPV in the cervix is a risk factor for cervical cytological 
abnormality, women were offered the opportunity to be informed of their test results if 
their cervical specimen tested positive for hrHPV. All women taking parted opted to 
be informed. Those who tested positive were contacted telephonically and provided 
with referral letters to their primary health care providers for cervical cytology smears 
and referral for abnormalities according to the South African National guidelines.
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4. Results 
 
4.1. Demographics, risk factors and clinical pre-eclampsia 
	
4.1.1. Description of demographics and risk factors 
 
Fifty women were identified as eligible for inclusion in the study and approached for 
consent. One declined to take part. Of the forty-nine who agreed to take part, one 
was excluded because of failed serum biomarker testing and eight were excluded 
because their cervical smear specimens were discarded before testing. Forty cases 
were thus included in the final analysis. The patient demographics are demonstrated 
in Table 4.1. 27 cases were recruited from Chris Hani Baragwanath Academic 
Hospital and 13 from Charlotte Maxeke Johannesburg Academic Hospital.  
 
The mean age of participants was 27.6 years (95% CI, 25.7 - 29.5). The mean BMI 
was 31.1 kg/m2 (29.1-33.1). The mean birth weight and gestation was 2696.6g 
(2415.6 - 2977.6) and 36.0 weeks (34.6 - 37.4) respectively. 26 (65%) women had 
previous pregnancies into the third trimester, i.e. were parous, and 9 (22.5%) women 
reported a previous non-viable pregnancy loss, including ectopic pregnancy, 
termination of pregnancy and miscarriage.  
 
The HIV status of all the women were tested during their pregnancy and recorded. 
Twelve (30%) women were HIV positive.  The women who tested HIV positive were 
all on anti-retroviral treatment. All continuous variables met the requirements for 
normality. 
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Table 4.1: Description of demographic and risk factor variables, including the 
association with clinical pre-eclampsia expressed as odds ratios [95% confidence 
interval(CI)] for binary variables or p-values (continuous variables) 
	  
Variable Cases Controls Total p-Value/OR 
Number 21 19 40  
Mean age, years [95%CI] 27.0  
[23.9 -30.0] 
28.3   
[25.7 - 30.8) 
27.6   
[25.7  - 29.5] 
p = 0.50  
(Unpaired t-test) 
By age group, n (%)     
20-25 9 (42.9%) 4 (21.1%) 13 (32.5%)  
26-30 6 (28.6%) 8 (42.1%) 14 (35.0%)  
31-35 2 (9.5%) 5 (26.3%) 7 (17.5%)  
36-40 4 (19.1%) 2 (10.5%) 6(15.0%)  
Mean BMI, kg/m2 [95%CI] 31.2  
[27.8 - 34.6] 
30.9  
[28.6 - 33.3] 
31.1  
[29.1 - 33.1] 
P = 0.44 
(Unpaired t-test) 
BMI by group, n (%)  
20-24.99 kg/m2 5 (23.8%) 1 (5.3%) 6 (15.0%)  
25-29.99 kg/m2 3 (14.3%) 7 (36.8%) 10 (25.0%)  
30-34.99 kg/m2 7 (33.3%) 9 (47.4%) 16 (40.0%)  
35-39.99 kg/m2 4 (19.1%) 1 (5.3%) 5 (12.5%)  
>40 kg/m2 2 (9.5%) 1 (5.3%) 3 (7.5%)  
Mean birthweight, g [95%CI] 2 232  
[1 805 -   
2 658] 
3 210  
[3 012 –  
3 407] 
2 696.6  
[2 415 –  
2 977] 
p = < 0.01 
(Unpaired t-test) 
Birthweight by group                                           
<1500 g 6 (28.6%) 0 (0%) 6 (15.0%)  
1500-2499 g 6 (18.6%) 0 (0%) 6 (15.0%)  
>2500 g 9 (42.9%) 19 (100%) 28 (70%)  
Mean gestation, weeks 
[95%CI] 
34.0  
[31.7 - 36.2] 
38.2  
[37.1 - 39.3] 
36.0  
[34.6 - 37.4] 
p = <0.01 
(Unpaired t-test) 
Gestation by group, n (%)  
< 28 weeks  
1 (4.8%) 
 
0 (0%) 
 
1 (2.5%) 
 
28-34 weeks 7 (33.3%) 0 (0%) 7 (17.5%)  
34-37 weeks 6 (28.6%) 3 (15.8%) 9 (22.5%)  
37-41 weeks 7 (33.3%) 14 (73.7%) 21 (52.5%)  
>41 weeks 0 (0%) 2 (10.5%) 2 (5.0%)  
Parous, n (%) 13 (61.9%) 13 (68.4%) 26 (65.0%) OR 0.8  
[0.2 – 3.3] 
(Pearson’s χ2) 
Previous pregnancy loss, n 
(%)  
3 (14.3%) 6 (31.6%) 9 (22.5%) OR 0.4  
[0.1 – 2.1] 
(Pearson’s χ2) 
HIV positive, n(%) 6 (28.6%) 6 (31.2%) 12 (30.0%) OR 0.9  
[0.2 – 4.2] 
(Pearson’s χ2) 
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4.1.2 Associations between demographics/risk factors 
 
Variables were tested for association using Pearson’s chi-squared test (for two binary 
variables), Student’s t-test (for a binary and continuous variables) or Pearson’s 
correlation (for two continuous variables). P-values for these measures of association 
are shown in table 2. 
 
Table 4.2: P-values for tests of association between demographic and risk factor 
variables, using Pearson’s chi-squared test (χ2) (for two binary variables), Student’s t-
test (t-test) (for a binary and continuous variable) or Pearson’s correlation (pc) (for 
two continuous variables). Significant values in bold. 
Variable Age BMI Birth 
weight 
Gestation Parity Previous 
pregnancy 
loss 
BMI 0.18 
(pc)   
- - - - - 
Birth 
weight 
0.85 
(pc) 
0.11 
(pc) 
- - - - 
Gestation 0.50 
(pc) 
0.09 
(pc) 
<0.01 
(pc) 
- - - 
Parity <0.01 
(t-test) 
0.03 
(t-test) 
0.86 
(t-test) 
0.85 
(t-test) 
- - 
Previous 
pregnancy 
loss 
0.01 
(t-test) 
0.54 0.14 0.10 
(t-test) 
0.09 
(χ2) 
- 
HIV 0.03 
(t-test) 
0.29 0.44 0.90  
(t-test) 
0.11 
(χ2) 
0.28 
(χ2) 
 
 
Age showed a significant association with parity with a mean age in parous women of 
30.4 [95% CI, 28.2 – 32.6] years versus a mean of 22.4 [95% CI, 21.0 – 23.7] years 
in nulliparous women. A similar effect was seen with previous non-viable pregnancy 
loss, with women who reported pregnancy loss having a mean age of 32.0 [95% CI, 
27.0 – 37.0] years, versus 26.3 [95% CI, 24.3 – 28.2] years in those without.  
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In addition, there was a significant association between HIV status and age, with a 
mean age of 30.8 [95% CI, 27.1 – 34.4] years in HIV positive women, and a mean 
age of 26.2 [95% CI, 24.0 – 28.4] in HIV negative women. Age showed no significant 
association with BMI, birthweight or gestation at birth. 
 
BMI showed a significant association with parity, with parous women having a BMI of 
32.7 [95% CI, 30.0 – 35.4] versus 28.1 [95% CI, 25.5 – 30.7) in nulliparous women. 
There were no significant associations between BMI and previous pregnancy loss or 
HIV. Birthweight and gestation trended towards a positive association with BMI when 
analysed with Spearman’s correlation, without reaching statistical significance (p = 
0.07 and 0.11). 
 
Birthweight and gestation showed a high degree of correlation (p = <0.01). Neither 
showed association with parity, previous pregnancy loss or HIV status. There were 
no significant associations between parity and HIV status or previous pregnancy loss. 
 
4.1.3 Demographic and risk factor variables and clinical pre-eclampsia 
 
Mean patient age had a similar distribution between cases (27.0 years [95% CI, 23.9 
– 30.0] and controls (28.3 years [95% CI, 25.7 – 30.8]). 
 
The mean BMI between case and control groups was similar (cases 31.2kg/m2 [95% 
CI, 27.8 - 34.6], controls 30.9kg/m2 [95% CI, 28.6 - 33.3]). The median BMI was 
30.5kg/m2 with range 21.0 – 50.8kg/m2.  
 
The majority (65%) of women were parous (defined as having had at least one 
previous pregnancy of more than 26 weeks’ gestation), with no significant difference 
(p = 0.67) between cases (60.9% [95% CI, 39.2 – 84.5%]) and controls (68.4% [95% 
CI, 45.4 – 91.4%]). Nine (22.5%) women had previous non-viable pregnancy loss 
with no significant difference (p = 0.19) between cases and controls. 
 
There was no significant difference in prevalence of HIV between cases and controls 
(p = 0.84). 
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Clinical pre-eclampsia showed no significant associations between patient age (p = 
0.50), BMI (p = 0.44), parity (p = 0.67), previous pregnancy losses (p = 0.19) and HIV 
status (p = 0.86). Adjusted odds ratios for clinical pre-eclampsia and HIV, previous 
pregnancy loss or multiparity as calculated using multiple logistic regression are 
shown in Table 4.3 below. 
 
Table 4.3: Adjusted odds ratios for developing clinical pre-eclampsia 
Risk factor    aOR    [95% CI] 
HIV status    1.0  [0.2 - 4.1] 
Previous pregnancy loss  2.7 [0.5 - 13.8] 
Multiparity    1.1 [0.3 - 4.4] 
 
Clinical pre-eclampsia was associated with a lower gestation (figure 1) and birth 
weight (figure 2) at delivery. In women with clinical pre-eclampsia mean birth weight 
was 2 232 [95% CI, 1 805 – 2 659] grammes and mean gestation 34.0 [95% CI, 31.1 
– 36.2] weeks. In women without pre-eclampsia mean birth weight was 3 210 grams 
[95% CI, 3 012.7 – 3 407.3] and mean gestation 38.2 weeks [95% CI, 37.1 – 39.3]. 
These differences were statistically significant with p-values of <0.01 for both birth 
weight and gestation, illustrated in Figures 4.1 and 4.2 below.  
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Figure 4.1: Comparison of gestation between case and control groups 
 
 
Figure 4.2: Comparison of birth weight between case and control groups 
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4.2 Demographics, risk factors and sFLT1 and PlGF levels 
 
Table 4.4: Comparison of mean serum levels of sFLT1 and PlGF and their ratio in 
case and control groups. 
 Cases Controls Total p-value 
Number 21 19 40  
Biomarkers   
sFLT1(pg/ml) 
10 810.9 (8 
256.8 – 13 
364.9) 
4 148.5 (3 
120.5 – 5 
176.5) 
7 646.2 (5 
906.3 – 9 
386.1) 
<0.01 
 
PlGF (pg/ml) 
114.4 (10.1 - 
218.7) 
270.6 (178.6 - 
362.6) 
188.6 (117.1 - 
260.1) 
0.03 
 
s-Flt/PlGF 
ratio 
379.2 (201.6 - 
556.7) 
41.9 (6.1 - 
77.7) 
219.0 (113.1 - 
324.9) 
<0.01 
 
The described association between clinical pre-eclampsia and decreased PlGF and 
raised sFLT1 held true in this sample, with a high degree of statistical significance for 
both measures, as well as for the ratio between the two, as shown above in table 4. 
The quantile plots in Figures 4.3, 4.4 and 4.5 below illustrate this relationship 
graphically. 
 
Figure 4.3: Comparison sFLT1 level measurements between case and control 
groups 
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Figure 4.4: Comparison of PlGF level measurements between case and 
control groups 
 
 
Figure 4.5: Comparison of sFLT1/PlGF ratio between case and control groups 
	 38	
Age showed a negative correlation with sFLT1 levels, but no significant effect on 
PlGF levels. BMI showed no correlation with either sFLT1 or PlGF levels. Gestation 
and birthweight had a negative correlation with both sFLT1 and PlGF levels and their 
ratio. 
 
Table 4.5: Testing for association between continuous variables and biomarkers 
using Pearson’s correlation  
 sFLT1 levels (pg/ml) PlGF levels (pg/ml) sFLT1/PlGF ratio 
Age 0.09 0.51 0.16 
BMI 0.59 0.34 0.59 
Gestation <0.01 0.43 <0.01 
Birth 
weight 
<0.01 0.40 <0.01 
 
Soluble fms-like tyrosine kinase-1 showed a trend towards lower levels in HIV 
positive women (6 310 pg/ml [95% CI, 3 485 – 9 135]) than in HIV negative women 
(8 219 pg/ml [95% CI, 5 972 – 10 465]), without statistical significance, with p-value 
0.32. PlGF tended to be higher in HIV positive women (241.4 pg/ml [95% CI, 48.5 – 
434.3]) than in HIV negative women (166.0 pg/ml [95% CI, 95.7 – 236.3]), again 
without reaching statistical significance. 
 
Both multiparity and previous pregnancy loss had a negative association with sFLT1 
and PlGF levels. This effect disappeared when comparing the means of the 
sFLT1/PlGF ratio. 
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Table 4.6: Testing for association between binary variables and biomarkers using 
unpaired Student’s t-test  
 
  
Variable Sflt1 (PG/ML) PlGF (PG/ML) Sflt1/PlGF RATIO 
 Mean  
[95% CI] 
P-
value 
Mean  
[95% CI] 
P-
value 
Mean  
[95% CI] 
P-
value 
HIV status                         
Positive 6 309.9  
[3 484.8 –  
9 135.0] 
0.32 241.35  
 [48.5 - 434.25] 
0.34 141.3 
[-11.6 - 
294.2] 
0.34 
Negative 8 218.9  
[9 5972.5 – 
10 465.4] 
165.97 
[95.7 - 236.3] 
252.3  
[112.0 - 
392.6] 
Parity                          
Nulliparous 10 049.8  
[6 967.2 - 
13 132.6] 
0.04 103.89  
[41.6 - 166.16] 
0.08 329.5  
[83.36    
575.65] 
0.12 
Multiparous 6351.96  
[4 277.8 -    
8 426.2] 
234.19  
[130.6 - 337.8] 
159.46  
[55.7 - 
263.2] 
Pregnancy loss                 
Yes 4 528.44  
[2 299.1 -   
6 757.8] 
0.05 184.7  
[45.8 - 323.7] 
0.95 78.49  
[-10.7    
167.7] 
0.15 
No 8 551.38  
[6 461.2 - 
10 641.6] 
189.696  
[102.7 - 276.7] 
259.76  
[126.8 - 
392.7] 
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When separate scatterplots of sFLT1 against birthweight for cases and controls are 
compared, two different distributions of sFLT1 levels may be observed. The first 
shows lower birthweight with higher levels of sFLT1, while the second group is 
clustered in higher birthweight but with lower sFLT1 levels. 
 
 
Figure 4.6: sFLT1 level and birthweight, by case and control groups 
 
4.3 Detection of placental and cervical HPV 
 
4.3.1 Placental HPV 
 
None of the collected samples tested positive for any HPV types detectable by the 
Roche Linear Array. This included placental tissue samples, as well as placental 
decidual surface smear specimens. In all tests DNA detection control strips were 
positive, indicating that negative results were not due to assay failure. 
 
As a result, no association between placental HPV and any of the patient 
characteristics, clinical pre-eclampsia or cervical HPV was found. 
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4.3.2 Cervical HPV 
 
 
Figure 4.7: HPV subtype prevalence, high-risk subtypes outlined in red. 
 
Of the 40 women in the study, 15 tested positive for both hrHPV and lrHPV subtypes. 
Five tested positive for hrHPV only and 5 tested positive for lrHPV only. Fifteen 
women tested negative for both hrHPV and lrHPV.   
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Figure 4.8: Number of HPV subtypes by participant 
 
Of the 25 women who tested positive for cervical HPV, seven women had only one 
subtype while 18 had co-infection with more than one subtype. The variety of 
subtypes detected in the sample was wide with 32 out of the 37 possible subtypes 
detectable by the Linear Array detected in at least one specimen. Similarly, there 
were not any marked predominant subtypes, with the highest prevalence for one 
subtype with six out of 40 (15%) samples for HPV-35, a high-risk type. Only six out of 
32 detected types showed a prevalence of 10% or more. 
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 Figure 4.9: High-risk HPV subtype prevalence 
 
Restricting attention to high-risk subtypes showed a similar picture. Distribution of 
high-risk subtypes was heterogenous with 14 separate high risk types detected (see 
figure 4.9). HPV-35 was the most prevalent with 15%, but the majority of other types 
infected at least 5% of women. 
 
Overall HPV detection showed no association with age (p-value = 0.402), BMI (p-
value = 0.3243), gestation (p-value = 0.9061) or birth weight (p-value = 0.4978) using 
unpaired t-test, or with parity (p = 0.231), previous pregnancy loss (p=0.769) or HIV 
status (p=0.722) using Pearson’s chi-squared test. 
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4.4 Association between cervical HPV and clinical pre-eclampsia 
 
Table 4.7: The association between cervical HPV and clinical pre-eclampsia 
 Cases Controls Total OR 
[95% CI] (p-
value) 
Number 21 19 40  
Any HPV  11 (52.4%) 14 (74,7%) 25 (62.5%) 0.39 [0.1 - 1.8] 
(p=0.16) 
hrHPV 10 (47.6%) 10 (52.6%) 20 (50.0%) 0.8 [0.2 – 3.4] 
(p = 0.75) 
lrHPV 9 (42.9%) 11 (57.9%) 20 (50.0%) 0.5 [0.1 – 2.3] 
(p = 0.34) 
Single subtype 1 (4.8%) 6 (32.6%) 7 (17.5%) p = 0.70 
(One-way 
ANOVA) 
Multiple subtypes 10 (47.6%) 8 (42.1%) 18 (45.0%) 
No subtypes detected 10 (47.6%) 5 (26.3%) 15 (37.5%) 
 
When combining all HPV positive women, there is a trend towards lower prevalence 
in pre-eclamptic women than in controls, without reaching statistical significance 
(p=0.17). When hrHPV and lrHPV are analysed separately, no association is 
apparent. Similarly, if women with single subtype infection and co-infection are 
compared to negative women using one-way ANOVA testing, no significant trend 
emerges (p = 0.70). 
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4.5 Association between cervical HPV and sFLT1 and PlGF levels 
 
When analysing the association between cervical HPV and the tested biomarkers 
some trends are revealed. Levels of sFLT1 tend to be higher in women who tested 
negative (9164 pg/ml [95% CI, 6 417 – 11 911]) than in women who tested positive  
(6 735.3 pg/ml [95% CI, 4 420 -  9 049]) for any cervical HPV, although this trend fell 
short of statistical significance (p = 0.17).  
 
There was no significant difference in mean PlGF values between women testing 
positive (202.0 pg/ml [95% CI,104.1 – 301.8]) and women testing negative (164.6 
pg/ml [95% CI, 53.9 – 275.3]) (p = 0.61). This is similar for the sFLT1/PlGF ratio, with 
positive women showing a mean of 201.9 [95% CI, 46.3 – 357.4] and negative 
women showing a mean of 247.4 [95% CI, 111.1 – 383.8] (p = 0.68). These 
relationships are illustrated in Figures 4.10 – 4.12. 
 
 
 Figure 4.10: sFLT1 levels by HPV status, cases versus controls 
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 Figure 4.11: PlGF levels by HPV status, cases versus controls 
 
 
 
 
 Figure 4.12: sFLT1/PlGF ratio by HPV status, cases versus controls 
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5. Discussion 
 
5.1 Demographics, risk factors and clinical pre-eclampsia 
 
The sample presented here was homogenous. The associations between age and 
parity and previous pregnancy loss can be explained by the higher likelihood for a 
woman to have had a previous pregnancy as she gets older. While the mean BMI in 
this group appears high, it should be borne in mind that these measurements were 
taken in the third trimester of pregnancy, when a reasonably expected weight gain 
during pregnancy of 10kg would add approximately 4kg/m2 to the BMI of a 160cm-tall 
woman. The association between BMI and parity is expected and has been 
described (123). The overall prevalence of HIV in this sample of 30% is congruent 
with reported rates of prevalence of HIV in pregnancy in South Africa (124). The 
association between HIV status and age also reflects the increasing probability of 
contracting HIV the longer the duration of a women’s reproductive activity. The 
association between birth weight and gestation is expected and unremarkable. 
 
There was a similar distribution of demographics and risk factors between women 
with and without clinical pre-eclampsia. None of the non-modifiable risk factors for 
pre-eclampsia were significantly different between the groups. The negative 
association between gestation and birth weight and clinical pre-eclampsia reflects 
earlier intervention and delivery in women with pre-eclampsia. 
 
Of interest is the similarity in distribution of parity between the groups, given that 
nulliparity is a described risk factor for pre-eclampsia (36). There is also no clear 
correlation between gestational age at delivery and parity in this sample. 
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5.2 Demographics, risk factors and biomarker levels 
 
Biomarker levels correlated well with the presence of clinical pre-eclampsia. The one 
outlier with very high sFLT1 levels but without clinical pre-eclampsia was a woman 
with large obstructive fibroids that mandated delivery by caesarean section. The 
effects of fibroids on VEGF levels have been previously described (125), but the 
effects on sFLT1 levels are unknown.  
 
A correlation between parity and previous pregnancy loss with increased sFlt1 levels 
was found. It is not possible to determine in this small sample whether the 
association is due to parity or age or to a combination of the two.  
 
5.3 Detection of HPV 
 
5.3.1 Detection of placental HPV  
 
The finding of no HPV detection in any placentae, although unexpected, is 
significant. There is considerable variation in the reported literature regarding the 
prevalence of placental HPV, ranging from 4.2% (114) to 57% (8). Several factors 
can be considered to be responsible for this. 
 
Firstly, the method of collection of the specimen is of particular interest. As 
demonstrated here, cervical HPV infection is very common. Viral particles were 
collected from the cervix in this study using a cervical brush which is atraumatic to 
tissues. It is therefore not inconceivable that the placenta may be contaminated with 
viral particles simply by passage through the cervix. While this may lead to detection 
of viral particles by PCR testing, it is unknown whether infection of trophoblast can 
take place after delivery of the placenta. In the studies that reported the prevalence 
of placental HPV (8, 114, 115) the route of delivery and incidence of rupture of 
membranes prior to delivery was not reported and it is uncertain whether that played 
a role in the detection of HPV. 
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Secondly, the method of testing may affect the findings. Previous studies which 
found low prevalence of HPV in the placenta made use of PCR testing (114, 115, 
116). The study which found higher prevalence made use of the L1 antibody staining 
(8). There are of course two possible explanations for this. First would be that L1 
antibody staining has a high level of interference and false positives. The second 
possibility is that PCR testing has an unacceptably low sensitivity. In the light of its 
high reliability and very high sensitivity (109) when used for cervical smear testing, 
this would appear unlikely. 
 
Based on the evidence in this study, the conclusion is that there is no evidence of 
detectable levels of HPV DNA in placental tissue, and consequently no relationship 
between placental HPV and clinical pre-eclampsia, or serum levels of sFLT1 and 
PlGF. 
 
5.3.2 Detection of cervical HPV 
 
Cervical HPV is very common in this sample. This is the first description of cervical 
HPV prevalence in a pregnant population in South Africa. Using the same testing, the 
findings were very similar to that found in the earlier study by Richter et al. The 
overall rate of HPV infection was 62.5% in this study compared to 74.6% found by 
Richter et al, high-risk HPV infection 50% compared to 54.3% and the presence of 
multiple subtypes 45% compared to 52.7%. However, the rates of cervical cytological 
abnormality found by Richter et al was much lower (17.6%) than the rates of HPV 
infection (105). 
 
This similarity with non-pregnant populations is congruent with findings from the 
United States of similar HPV prevalence rates between pregnant (42%) and non-
pregnant women (41%) (107). A previous meta-analysis of 14 studies from Asia, 
Europe, North America and Australia found an overall rate of 16.8% against 12.3% in 
non-pregnant women, although with variations in prevalence in pregnant women from 
9.6% in Italy to 37.1% in Mexico (126). 
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5.4 Cervical HPV and pre-eclampsia 
 
No association between HPV detection and clinical pre-eclampsia could be 
demonstrated in this sample, and indeed, the observed values showed the opposite 
of the hypothesis with lower rather than higher prevalence of pre-eclampsia in 
women with cervical HPV. This observation differs from what is expected from the 
findings of McDonnold et al, where a positive association was found between implied 
cervical HPV infection and clinical pre-eclampsia. (7).  
 
5.5 Cervical HPV and sFLT1 and PlGF 
 
The relationship between cervical HPV and sFLT1 and PlGF levels was opposite to 
what was hypothesized, with consistent higher sFLT1 and lower PlGF. It remains to 
be determined whether this relationship would hold true in a larger sample, to reach 
statistical significance. Based on the findings here, with mean sLFT1 levels of  
4 148 pg/l in the HPV negative group and 3 895 pg/l in the HPV positive group, with a 
standard deviation of 2 132 pg/l, and assuming an HPV prevalence of 62.5%, using a 
standard power calculation a group with more than 306 participants would be 
necessary to reach statistical significance. 
 
The hypothesis that HPV would be associated with clinical pre-eclampsia and with 
raised levels of sFLT1 was thus not borne out. There are three assumptions that 
underpin this hypothesis that deserves re-examination.  
 
McDonnold et al found that cervical cytological abnormality was associated with 
clinical pre-eclampsia (7). The first assumption is that cervical cytological abnormality 
is associated with cervical HPV infection. The corollary is that clinical pre-eclampsia 
must be associated with cervical HPV. The third assumption is that clinical pre-
eclampsia is associated with raised sFLT1 levels. 
 
The association between pre-eclampsia and sFLT1 levels stood up in this sample. 
The association between cervical HPV infection and cervical cytological abnormality 
on the other hand is worth considering. While it is generally accepted that HPV is the 
aetiological agent in abnormal cervical cytology, infection does not inevitably lead to 
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cytological changes, and indeed the majority of infections are cleared without 
neoplasia developing (105).  
 
This poses the question whether a temporal relationship exists between HPV 
infection and effects on the VEGF system. HPV DNA detection does not imply 
integration into the cellular DNA, or cytological abnormality (105). It can be 
postulated that the presence of cytological abnormality changes the effects that HPV 
has on the developing pregnancy. 
 
In addition, whether early HPV infection, which is associated with the expression of 
E5 (101), is associated with lower levels of sFLT1, whereas later stages of infection, 
associated with abnormal cervical cytology and where E5 expression has been lost 
(101), is associated with higher levels and more pre-eclampsia may be grounds for 
future research. 
 
Whether these effects will also be demonstrable in the first trimester would be of 
interest. When one considers the known association between HPV and spontaneous 
miscarriage (6) and the known association between lower first trimester sFLT1 levels 
and miscarriage (97), this raises the possibility that its effects on sFLT1 levels may 
be the link between HPV and miscarriage. In addition, should such a link exist, the 
molecular mechanisms whereby HPV affects sFLT1 levels and VEGF remain to be 
elucidated. 
 
In a thought experiment, its association with first trimester miscarriage and potentially 
protective role against pre-eclampsia raises the possibility of a symbiotic role for HPV 
in the human cervix. It is well known that historically the third trimester of pregnancy, 
in addition to childbirth, held very high morbidity and mortality in the era before 
modern obstetrics (24). Any agent that would first act as an abortifacient in the first 
trimester, when morbidity and mortality were lower, and secondly decrease the 
incidence of one of the major complications of pregnancy, would conceivably confer 
reproductive advantage.  
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The oncogenic effects of HPV would only have its deleterious effects on survival 
later, after its effects on reproduction. This stimulates further interesting questions on 
the full role of this ubiquitous virus in the human organism. 
 
5.6 Conclusion 
 
In conclusion, in the absence of any HPV in placental samples, no association was 
found between the presence of HPV in the placenta at delivery and clinical pre-
eclampsia. Similarly, no association could be demonstrated between placental HPV 
and sFLT1 and PlGF levels, or with cervical HPV, or between different methods of 
testing the placenta. 
 
There was no association between cervical HPV and clinical pre-eclampsia found. 
There was a non-significant trend towards lower sFLT1 levels in subjects with 
cervical HPV. 
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7.4 Appendix D: Data collection instrument 
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7.5 Appendix E: Patient information sheet and consent form 
 
PARTICIPANT INFORMATION DOCUMENT 
 
Study title: The association between incidence of placental human 
papillomavirus detection and pre-eclampsia in adult women giving birth in two 
academic hospitals in Johannesburg 
 
Good day, my name is Francois Retief and I would like to invite you to take part in a 
study I am conducting. I am a doctor in this hospital and I work in the maternity 
department. I am doing research on the causes of high blood pressure in pregnancy.  
 
In this study I want to learn whether the presence of human papillomavirus (HPV) in 
the placenta is associated with a disease called pre-eclampsia. This is a disease that 
occurs in pregnant women that causes high blood pressure and passing of protein in 
the urine, and may cause severe organ damage and even death. HPV is a virus that 
infects the female reproductive tract and may cause warts but may also be present 
without any outward sign, and in some forms causes cancer of the cervix. In addition, 
I will be comparing two different ways of testing the placenta for HPV, and testing 
whether having HPV in your placenta changes some of the substances your placenta 
releases into your blood. 
 
I would like to invite you to take part in this study. In this study I will be comparing the 
placentas of women with high blood pressure with the placentas of healthy women to 
detect human papillomavirus. After testing the placenta will be destroyed, the same 
as it would be if you didn’t take part in the study. In addition, I will be testing your 
cervix for the papillomavirus, similar to undergoing a pap smear test. Your blood will 
also be tested for two substances made by the placenta that are increased in pre-
eclampsia, namely soluble fms-like tyrosine kinase and placental growth factor. 
 
If you agree to take part, your doctor will ask you some questions about your risk 
factors for pre-eclampsia, and look for some information in your file. This will take 
about five minutes of your time. 
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Before your caesarean section, your doctor will collect a blood sample from you. This 
blood will be tested for soluble fms-like tyrosine kinase and placental growth factor, 
two substances in your blood that is made by your placenta, and that are increased 
in women with pre-eclampsia. Also before your caesarean section the doctor will also 
do a cervical smear on your cervix. To do this they will pass a speculum into the 
vagina, and brush your cervix gently to obtain some of the cells lining your cervix. 
This will be done after you have received your anaesthetic, so you will experience no 
additional discomfort, and it holds no extra risk for you. When your baby has been 
delivered a piece of your placenta will be collected to test, as well as brushing your 
placenta to collect cells to test for the papillomavirus.  
 
There is no risk to you or your baby in taking part in this study. Because the test on 
your cervix may reveal that you have an increased risk of developing cervical cancer 
in the future, doing this test may benefit you by discovering this earlier. The 
information we get from this study may benefit other women in the future.  
 
You will be requested to provide your contact details, as well as the details of your 
preferred primary care provider (clinic or GP) so if your cervical smear test indicates 
increased risk, I will contact you with your result via your preferred means of 
communication, and provide you with a referral to your preferred health care facility. 
 
If you prefer not to, you are under no obligation to take part in this study. If you 
choose not to take part, you and your baby will receive exactly the same care and 
treatment. You may decide at any time not take part any more. If you decide to 
withdraw from the study, the care and treatment you and your baby receives will not 
be affected in any way. If you wish to withdraw from this study, you can do so by 
contacting me at the phone number or email provided, and your information will be 
withdrawn from the study. 
 
You will be provided with any additional information that becomes available during 
the course of the study, which may influence your decision to take part in the study.  
 
You will not be paid to take part in this study, and it will not cost you anything to 
participate in this study. 
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Your personal information will be kept confidential and secret and will only be made 
available with your permission or as required by law. Any information that can identify 
you personally will be removed once your information has been collected. A separate 
record of study participants will be kept securely in order to be able to trace your 
information, should you wish to withdraw your consent to take part, and to contact 
you with your results, if they are positive. 
 
You can contact me on phone 082 545 0768, or email 1017956@students.wits.ac.za, 
if you have any questions or if you wish to withdraw your consent. If you have any 
questions about your rights as a participant, or have any concerns about the conduct 
of the study, you may contact Prof Cleaton-Jones, Chairman of the University of the 
Witwatersrand Human Research Ethics Committee (Medical), which is an 
independent committee established to protect the rights of research participants, at 
011 717 2301. 
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CONSENT FORM 
 
I, ……………….., confirm that the information contained in this form has been 
explained to me in a language that I understand, and I am willing to take part in this 
study.  
 
☐ I WOULD like to be informed if my test results show increased risk 
☐ I WOULD NOT like to be informed if my test results show increased risk 
 
My preferred contact details are: 
 
………………………………………………………………………… 
………………………………………………………………………… 
………………………………………………………………………… 
 
My preferred health care facility is: 
 
…………………………………………………………………………. 
 
 
I understand that I can withdraw this consent at any time.  
 
 
Signed    ……………….. at (place) ………………..   on (date) ……………….. 
 
By (print name) ………………. 
 
Witness         ..……………… 
 
Investigator         …….…………. 
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7.6 Appendix F: Linear Array package insert 
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7.7 Appendix G: Elecsys sLFT1 and PlGF assay package inserts 
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7.8 Appendix H: Plagiarism declaration 
 
 
 
 
 
  
1 
 
 
 
PLAGIARISM DECLARATION TO BE SIGNED BY ALL HIGHER DEGREE STUDENTS 
SENATE PLAGIARISM POLICY: APPENDIX ONE 
I _______________________________________ (Student number: _________________) am a student  
registered for the degree of ____________________________________ in the academic year _______. 
 
I hereby declare the following: 
- I am aware that plagiarism (the use of someone else’s work without their permission and/or 
without acknowledging the original source) is wrong. 
- I confirm that the work submitted for assessment for the above degree is my own unaided work 
except where I have explicitly indicated otherwise. 
- I have followed the required conventions in referencing the thoughts and ideas of others. 
- I understand that the University of the Witwatersrand may take disciplinary action against me if 
there is a belief that this is not my own unaided work or that I have failed to  acknowledge the 
source of the ideas or words in my writing. 
- I have included as an appendix a report from “Turnitin” (or other approved plagiarism detection) 
software indicating the level of plagiarism in my research document. 
 
 
Signature: _________________________  Date: ________________________ 
 
 
Pieter Francois Retief 1017956
Master of Medicine (Obstetrics & Gynaecology) 2017
23 January 2017
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